NSRX
Nasus Pharma Ltd.
NYSE MKT: NSRX · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$2.75
+1.85% today
Updated 2026-05-01
Market cap
$37.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$0 – $10
Volume
0.2M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.5
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$20.00
+627.27%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-4.93M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-1.71M | $-1.05M | $-1.53M | $-5.86M | $-5.86M |
| EPS | — | — | — | — | $-0.72 |
| Free cash flow | $-1.21M | $-1.03M | $-665000.00 | $-4.93M | $-4.93M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Nasus Pharma Ltd. trades at $2.75. Our Smart Value Score of 17/100 indicates the stock is weak.
Frequently asked questions
What is Nasus Pharma Ltd.'s stock price?
Nasus Pharma Ltd. (NSRX) trades at $2.75.
Is Nasus Pharma Ltd. overvalued?
Smart Value Score 17/100 (Grade F, Strong Sell).
What is the price target of Nasus Pharma Ltd. (NSRX)?
The analyst target price is $20.00, representing +627.3% upside from the current price of $2.75.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE MKT
CurrencyUSD
Quick metrics
P/S ratio—
ROE—
Beta—
50D MA$3.57
200D MA$6.24
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—